Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ALVR

AlloVir Inc

May 08 • 03:36PM ET

0.7959

Dollar change -0.0004
Percentage change -0.05	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO IWC FESM VTWV URTY

Index	RUT	P/E	-	EPS (ttm)	-1.83	Insider Own	49.91%	Shs Outstand	113.97M	Perf Week	-1.74%
Market Cap	91.46M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-0.33%	Shs Float	57.56M	Perf Month	6.99%
Income	-190.42M	PEG	-	EPS next Q	-0.16	Inst Own	42.83%	Short Float	11.12%	Perf Quarter	18.42%
Sales	0.00M	P/S	-	EPS this Y	77.21%	Inst Trans	24.79%	Short Ratio	11.56	Perf Half Y	-50.87%
Book/sh	1.28	P/B	0.62	EPS next Y	28.87%	ROA	-81.40%	Short Interest	6.40M	Perf Year	-81.79%
Cash/sh	1.60	P/C	0.50	EPS next 5Y	-	ROE	-102.85%	52W Range	0.62 - 6.12	Perf YTD	17.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-70.96%	ROI	-117.23%	52W High	-87.00%	Beta	0.79
Dividend TTM	-	Quick Ratio	6.61	Sales past 5Y	-37.09%	Gross Margin	-	52W Low	27.73%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	6.61	EPS Y/Y TTM	19.73%	Oper. Margin	0.00%	RSI (14)	54.72	Volatility	3.08% 4.44%
Employees	112	Debt/Eq	0.19	Sales Y/Y TTM	-	Profit Margin	-	Recom	4.25	Target Price	0.83
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-27.88%	Payout	-	Rel Volume	0.39	Prev Close	0.80
Sales Surprise	-	EPS Surprise	6.07%	Sales Q/Q	-	Earnings	Nov 02 BMO	Avg Volume	553.82K	Price	0.80
SMA20	2.19%	SMA50	4.80%	SMA200	-48.87%	Trades		Volume	205,137	Change	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-26-23	Downgrade	BofA Securities	Buy → Underperform	$17 → $1
Dec-22-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-22-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-22-23	Downgrade	JP Morgan	Overweight → Underweight
Aug-18-23	Initiated	BofA Securities	Buy	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$48
Aug-24-20	Initiated	SVB Leerink	Outperform	$41
Aug-24-20	Initiated	Morgan Stanley	Overweight	$49
Aug-24-20	Initiated	JP Morgan	Overweight	$50

Mar-18-24 03:53PM	ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023 (InvestorPlace) -6.03%
Mar-13-24 11:53AM	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights ALVR (GlobeNewswire)
10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir (PR Newswire)
Mar-12-24 05:50AM	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR (PR Newswire)
Mar-06-24 06:17PM	ALVR INVESTORS: Lead Plaintiff Deadline is Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire)
05:37PM	Loading…
Mar-04-24 05:37PM	AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline (GlobeNewswire)
Feb-28-24 01:06AM	AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline (GlobeNewswire)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-26-24 12:27PM	AlloVir, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALVR (GlobeNewswire)
Feb-23-24 10:30AM	ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-29-24 09:40AM	Are Medical Stocks Lagging AlloVir (ALVR) This Year? (Zacks)
Jan-24-24 09:45AM	ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-12-24 09:35AM	Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR) (Zacks) +5.30%
Jan-05-24 11:03AM	AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts (InvestorPlace)
08:37AM	Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce (FierceBiotech.com)
10:04AM	Loading…
Dec-26-23 10:04AM	Karuna downgraded, Arm target raised: Wall Street's top analyst calls (The Fly)
Dec-22-23 09:31AM	Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls (The Fly) -67.15%
08:30AM	AlloVir's shares plunge 64% as cell therapy biotech weighs options in wake of triple phase 3 disaster (FierceBiotech.com)
07:10AM	AlloVir scraps late-stage studies testing antiviral cell therapy (Reuters)
07:00AM	AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-16-23 07:00AM	AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-02-23 10:04AM	AlloVir Inc (ALVR) Reports Q3 2023 Financial Results (GuruFocus.com) +13.64%
07:00AM	AlloVir Reports Third Quarter 2023 Financial Results (Business Wire)
Sep-21-23 02:44PM	Why AlloVir Stock Dropped Today (Motley Fool)
Sep-14-23 09:59AM	These 2 Strong Buy Penny Stocks Could Soar to $17 (Or Higher), Say Analysts (TipRanks) +9.72%
Aug-28-23 07:00AM	AlloVir to Present at Upcoming Investor Conferences (Business Wire) +7.00%
Aug-03-23 07:00AM	AlloVir Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) +7.55%
Jul-12-23 03:12AM	Gilead Just Bought $30 Million More of 2 Biotech Stocks (Barrons.com) +6.76%
07:34AM	Loading…
Jul-04-23 07:34AM	Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26% (Zacks)
Jul-03-23 03:59AM	5 hot insider trades & hedge fund hits: Buffett picks up more Occidental shares (Investing.com)
Jun-27-23 12:00PM	AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why (Zacks)
Jun-23-23 01:56PM	Why Shares of AlloVir Plummeted This Week (Motley Fool)
Jun-21-23 09:20PM	AlloVir Announces Pricing of Public Offering of Common Stock (Business Wire)
04:18PM	AlloVir Announces Proposed Public Offering of Common Stock (Business Wire)
Jun-09-23 11:04AM	Why Shares of AlloVir Jumped This Week (Motley Fool) -7.83%
Jun-05-23 07:00AM	AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023) (Business Wire) +12.63%
May-16-23 07:00AM	AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer (Business Wire)
May-04-23 07:00AM	AlloVir Reports First Quarter 2023 Financial Results (Business Wire) +10.36%
May-01-23 07:00AM	AlloVir to Present at the BofA Securities 2023 Health Care Conference (Business Wire) +8.14%
Apr-26-23 05:12PM	AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections (Benzinga)
07:00AM	AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023 (Business Wire)
Mar-30-23 11:12AM	We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully (Simply Wall St.) -5.67%
Feb-23-23 04:15PM	AlloVir Appoints Derek Adams, Ph.D., to Board of Directors (Business Wire) +7.14%
Feb-15-23 10:05AM	AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall (Benzinga) -5.17%
07:07AM	AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook (Business Wire)
07:00AM	AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia (Business Wire)
Feb-10-23 09:55AM	Wall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know (Zacks)
Feb-07-23 10:17AM	Sage and Biogen's NDA for Depression Drug Gets Priority Review (Zacks)
Feb-01-23 07:00AM	AlloVir to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-25-23 12:00PM	AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8% (Zacks)
09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Jan-09-23 07:00AM	AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023 (Business Wire)
Jan-03-23 07:00AM	AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-10-22 05:15PM	AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition (Business Wire)
Nov-15-22 07:00AM	AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference (Business Wire) -5.21%
Nov-03-22 09:07AM	Final Data from AlloVirs Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting (Business Wire)
07:00AM	AlloVir Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-21-22 08:30AM	We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-06-22 09:55AM	Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High? (Zacks) -5.10%
Aug-31-22 07:00AM	AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire) +19.97%
Aug-19-22 09:55AM	Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect? (Zacks)
Aug-04-22 07:00AM	AlloVir Reports Second Quarter 2022 Financial Results (Business Wire) +12.22%
Aug-03-22 09:55AM	Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know (Zacks) +5.06%
Aug-01-22 08:09AM	Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares? (Simply Wall St.)
Jul-27-22 07:00AM	AlloVir Announces $126.6 Million Registered Direct Offering (Business Wire) +11.93%
Jun-07-22 12:07PM	AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients (Benzinga)
08:30AM	AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients (Business Wire)
May-05-22 07:00AM	AlloVir Reports First Quarter 2022 Financial Results (Business Wire)
Apr-21-22 11:35AM	AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel (Zacks) -13.28%
Apr-20-22 07:00AM	FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients (Business Wire) +15.53%
Apr-04-22 07:40PM	Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation (Simply Wall St.)
Mar-31-22 07:00AM	AlloVir Appoints Shawn Tomasello to Its Board of Directors (Business Wire) -6.77%
Mar-23-22 09:56AM	AlloVir (ALVR) Begins Study to Prevent Six Viral Infections (Zacks)
Mar-22-22 07:00AM	AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients (Business Wire) +7.25%
Feb-11-22 07:00AM	AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-10-22 07:00AM	AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook (Business Wire)
Jan-05-22 07:30AM	FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation (Business Wire)
Jan-03-22 04:05PM	AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-21 04:05PM	AlloVir Announces Departure of Chief Medical Officer Augustin Melian (Business Wire) -6.32%
Dec-11-21 01:00PM	AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting (Business Wire)
Nov-17-21 11:57AM	Allovir Insider Sold Over $465K In Company Stock (Benzinga)
Nov-15-21 07:00AM	AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (Business Wire)
Nov-10-21 11:48AM	Allovir Insider Trades $300K In Company Stock (Benzinga)
Nov-05-21 07:00AM	AlloVir Reports Third Quarter 2021 Financial Results (Business Wire)
Oct-29-21 09:47AM	Morgan Stanley: These 2 Strong Buy Stocks Could Double From Here (TipRanks)
Oct-06-21 11:31AM	Notable Allovir Insider Makes $445K Sale (Benzinga)
Oct-05-21 06:48AM	Companies Like AlloVir (NASDAQ:ALVR) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-04-21 07:00AM	FDA Grants Orphan Drug Designation (ODD) to AlloVirs Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis (Business Wire) -12.20%
Sep-29-21 02:09PM	Hedge Funds Are Buying AlloVir, Inc. (ALVR) (Insider Monkey)
07:00AM	Data Presented at IDWeek 2021 Demonstrate that ALVR109, AlloVirs Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta (Business Wire)
Sep-07-21 07:00AM	AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (Business Wire)
Sep-03-21 08:19AM	Biotech Is Due for a Comeback. 5 Stocks That Could Lead a Revival. (Barrons.com)
Aug-26-21 01:41PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Avalara, Inc. - ALVR (Newsfile)
Aug-06-21 07:00AM	AlloVir Reports Second Quarter 2021 Financial Results (Business Wire)
Jun-27-21 03:19AM	Should You Take Comfort From Insider Transactions At AlloVir, Inc. (NASDAQ:ALVR)? (Simply Wall St.)
May-06-21 07:00AM	AlloVir Reports First Quarter 2021 Financial Results (Business Wire)
Apr-07-21 09:45PM	Analysts Say These 3 Stocks Are Their Top Picks for 2021 (TipRanks)

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brainard Diana	Chief Executive Officer	May 03 '24	Sale	0.80	10,240	8,151	792,695	May 07 04:15 PM
Sinha Vikas	See Remarks	May 03 '24	Sale	0.80	4,957	3,946	1,133,139	May 07 04:15 PM
Miller Edward	General Counsel	May 03 '24	Sale	0.80	2,311	1,840	220,916	May 07 04:15 PM
Hagen Brett R	Chief Accounting Officer	May 03 '24	Sale	0.80	1,597	1,271	76,022	May 07 04:15 PM
Sinha Vikas	See Remarks	Apr 22 '24	Sale	0.75	1,857	1,393	1,138,096	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 22 '24	Sale	0.75	757	568	223,227	Apr 23 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 22 '24	Sale	0.75	480	360	77,619	Apr 23 04:15 PM
Brainard Diana	Chief Executive Officer	Apr 19 '24	Sale	0.75	9,601	7,207	802,935	Apr 23 04:15 PM
Sinha Vikas	See Remarks	Apr 19 '24	Sale	0.75	1,521	1,142	1,139,953	Apr 23 04:15 PM
Miller Edward	General Counsel	Apr 19 '24	Sale	0.75	626	470	223,984	Apr 23 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 19 '24	Sale	0.75	473	355	78,099	Apr 23 04:15 PM
Brainard Diana	Chief Executive Officer	Apr 02 '24	Sale	0.77	1,533	1,183	812,536	Apr 04 04:15 PM
Sinha Vikas	See Remarks	Apr 02 '24	Sale	0.77	885	683	1,141,474	Apr 04 04:15 PM
Miller Edward	General Counsel	Apr 02 '24	Sale	0.77	368	284	224,610	Apr 04 04:15 PM
Hagen Brett R	Chief Accounting Officer	Apr 02 '24	Sale	0.77	281	217	78,572	Apr 04 04:15 PM
Brainard Diana	Chief Executive Officer	Feb 21 '24	Sale	0.71	5,155	3,650	814,069	Feb 22 04:18 PM
Brainard Diana	Chief Executive Officer	Feb 20 '24	Sale	0.70	3,097	2,153	819,224	Feb 22 04:18 PM
Sinha Vikas	See Remarks	Feb 20 '24	Sale	0.70	2,893	2,011	1,142,359	Feb 22 04:15 PM
Hagen Brett R	Chief Accounting Officer	Feb 20 '24	Sale	0.70	494	343	78,853	Feb 22 04:15 PM
Miller Edward	General Counsel	Feb 20 '24	Sale	0.70	385	268	224,978	Feb 22 04:16 PM
Hagen Brett R	Chief Accounting Officer	Feb 08 '24	Sale	0.67	11,150	7,494	79,347	Feb 09 08:01 PM
Brainard Diana	Chief Executive Officer	Feb 05 '24	Sale	0.67	41,421	27,752	822,321	Feb 06 04:38 PM
Sinha Vikas	See Remarks	Feb 05 '24	Sale	0.67	18,331	12,282	1,145,252	Feb 06 04:46 PM
Miller Edward	General Counsel	Feb 05 '24	Sale	0.67	8,869	5,942	225,363	Feb 06 04:40 PM
Hagen Brett R	Chief Accounting Officer	Feb 05 '24	Sale	0.67	5,792	3,881	90,497	Feb 06 04:39 PM
Brainard Diana	Chief Executive Officer	Jan 23 '24	Sale	0.67	9,500	6,369	863,742	Jan 25 04:15 PM
Sinha Vikas	See Remarks	Jan 23 '24	Sale	0.67	3,205	2,150	1,163,583	Jan 25 04:15 PM
Miller Edward	General Counsel	Jan 23 '24	Sale	0.67	1,302	873	234,232	Jan 25 04:15 PM
Hagen Brett R	Chief Accounting Officer	Jan 23 '24	Sale	0.67	901	604	96,289	Jan 25 04:15 PM
Brainard Diana	Chief Executive Officer	Jan 04 '24	Sale	0.64	1,664	1,063	873,242	Jan 08 04:15 PM
Sinha Vikas	See Remarks	Jan 04 '24	Sale	0.64	961	614	1,166,788	Jan 08 04:15 PM
Miller Edward	General Counsel	Jan 04 '24	Sale	0.64	424	271	235,534	Jan 08 04:15 PM
Hagen Brett R	Chief Accounting Officer	Jan 04 '24	Sale	0.64	310	198	97,190	Jan 08 04:15 PM
Hagen Brett R	Chief Accounting Officer	Dec 27 '23	Sale	0.74	28,335	20,838	97,500	Jan 02 07:36 PM
Brainard Diana	Chief Executive Officer	Nov 20 '23	Sale	1.69	4,382	7,408	874,906	Nov 21 05:00 PM
Brainard Diana	Chief Executive Officer	Nov 17 '23	Sale	1.63	2,689	4,386	879,288	Nov 21 05:00 PM
Sinha Vikas	See Remarks	Nov 17 '23	Sale	1.63	2,490	4,061	1,167,749	Nov 21 05:00 PM
Hagen Brett R	Chief Accounting Officer	Nov 17 '23	Sale	1.63	403	657	125,835	Nov 21 05:00 PM
Sinha Vikas	See Remarks	Oct 20 '23	Sale	1.54	1,475	2,273	1,170,239	Oct 23 05:00 PM
Hagen Brett R	Chief Accounting Officer	Oct 20 '23	Sale	1.54	357	550	126,238	Oct 23 05:00 PM
Brainard Diana	Chief Executive Officer	Oct 19 '23	Sale	1.58	8,581	13,558	881,977	Oct 23 05:00 PM
Sinha Vikas	See Remarks	Oct 19 '23	Sale	1.58	1,232	1,947	1,171,714	Oct 23 05:00 PM
Hagen Brett R	Chief Accounting Officer	Oct 19 '23	Sale	1.58	358	566	126,595	Oct 23 05:00 PM
Brainard Diana	Chief Executive Officer	Oct 03 '23	Sale	1.98	1,325	2,619	890,558	Oct 05 05:00 PM
Sinha Vikas	See Remarks	Oct 03 '23	Sale	1.98	755	1,492	1,172,946	Oct 05 05:00 PM
Hagen Brett R	Chief Accounting Officer	Oct 03 '23	Sale	1.98	222	439	126,953	Oct 05 05:00 PM
Brainard Diana	Chief Executive Officer	Aug 18 '23	Sale	2.79	4,055	11,313	891,883	Aug 21 05:00 PM
Brainard Diana	Chief Executive Officer	Aug 17 '23	Sale	2.50	11,361	28,351	895,938	Aug 21 05:00 PM
Sinha Vikas	See Remarks	Aug 17 '23	Sale	2.50	10,516	26,243	1,173,701	Aug 21 05:00 PM
Hagen Brett R	Chief Accounting Officer	Aug 17 '23	Sale	2.50	1,653	4,125	127,175	Aug 21 05:00 PM
Sinha Vikas	See Remarks	Jul 20 '23	Sale	3.35	1,437	4,810	1,184,217	Jul 21 05:00 PM
Hagen Brett R	Chief Accounting Officer	Jul 20 '23	Sale	3.35	342	1,145	128,828	Jul 21 05:00 PM
Brainard Diana	Chief Executive Officer	Jul 19 '23	Sale	3.56	8,342	29,710	907,299	Jul 21 05:00 PM
Sinha Vikas	See Remarks	Jul 19 '23	Sale	3.56	1,198	4,267	1,185,654	Jul 21 05:00 PM
Hagen Brett R	Chief Accounting Officer	Jul 19 '23	Sale	3.56	342	1,218	129,170	Jul 21 05:00 PM
Brainard Diana	Chief Executive Officer	Jul 05 '23	Sale	3.05	5,275	16,063	915,641	Jul 06 05:00 PM
Sinha Vikas	See Remarks	Jul 05 '23	Sale	3.05	2,983	9,084	1,186,852	Jul 06 05:00 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 27 '23	Buy	3.75	2,930,870	10,990,762	16,635,286	Jun 28 05:17 PM
Hagen Brett R	Chief Accounting Officer	Jun 09 '23	Sale	5.64	5,045	28,453	129,512	Jun 13 05:00 PM
Brainard Diana	Chief Executive Officer	May 18 '23	Sale	4.21	4,536	19,115	916,628	May 19 05:00 PM

Open in Screener

ITOS

ITeos Therapeutics Inc

May 08 • 03:36PM ET

12.30

Dollar change -0.01
Percentage change -0.08	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ITOS ITeos Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN IBB SCHA DFAT VTWO VHT DFAC

Index	RUT	P/E	-	EPS (ttm)	-3.15	Insider Own	20.37%	Shs Outstand	35.84M	Perf Week	4.41%
Market Cap	442.43M	Forward P/E	-	EPS next Y	-5.99	Insider Trans	0.00%	Shs Float	28.64M	Perf Month	-2.77%
Income	-112.64M	PEG	-	EPS next Q	-0.98	Inst Own	80.82%	Short Float	7.41%	Perf Quarter	22.88%
Sales	12.60M	P/S	35.11	EPS this Y	-46.75%	Inst Trans	-2.42%	Short Ratio	7.25	Perf Half Y	20.47%
Book/sh	16.05	P/B	0.77	EPS next Y	-29.55%	ROA	-15.84%	Short Interest	2.12M	Perf Year	-12.70%
Cash/sh	14.79	P/C	0.83	EPS next 5Y	-	ROE	-18.19%	52W Range	8.20 - 18.24	Perf YTD	12.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-40.62%	ROI	-19.42%	52W High	-32.57%	Beta	1.29
Dividend TTM	-	Quick Ratio	13.76	Sales past 5Y	-23.53%	Gross Margin	93.02%	52W Low	50.00%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	13.76	EPS Y/Y TTM	-215.69%	Oper. Margin	-1198.71%	RSI (14)	59.38	Volatility	6.22% 5.04%
Employees	157	Debt/Eq	0.01	Sales Y/Y TTM	-95.29%	Profit Margin	-894.35%	Recom	1.00	Target Price	34.40
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-257.87%	Payout	-	Rel Volume	0.37	Prev Close	12.31
Sales Surprise	-100.00%	EPS Surprise	17.73%	Sales Q/Q	-100.00%	Earnings	Mar 06 BMO	Avg Volume	292.72K	Price	12.30
SMA20	9.04%	SMA50	6.45%	SMA200	10.96%	Trades		Volume	102,017	Change	-0.08%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-21	Initiated	H.C. Wainwright	Buy	$37
Oct-08-20	Initiated	Robert W. Baird	Outperform	$45
Aug-18-20	Initiated	Wedbush	Outperform	$45
Aug-18-20	Initiated	SVB Leerink	Outperform	$45
Aug-18-20	Initiated	Piper Sandler	Overweight	$50
Aug-18-20	Initiated	JP Morgan	Overweight	$40

Apr-07-24 04:30PM	iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-06-24 02:51PM	ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +7.80%
07:01AM	iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors (GlobeNewswire)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 04:30PM	iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
07:00AM	Loading…
Mar-01-24 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.23%
Feb-26-24 06:11AM	Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Jan-08-24 07:00AM	iTeos Announces 2024 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Jan-03-24 07:00AM	iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? (Zacks) -5.44%
Nov-21-23 07:00AM	iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-13-23 09:55AM	Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-10-23 09:55AM	Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know (Zacks)
Nov-07-23 07:00AM	iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
03:01AM	Loading…
Oct-31-23 03:01AM	Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +7.48%
Oct-16-23 01:46PM	Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More (Insider Monkey)
04:38AM	iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar? (Zacks)
Oct-11-23 05:55PM	NCR Atleos Set to Join S&P SmallCap 600 (PR Newswire) -6.72%
Sep-06-23 07:00AM	iTeos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-23 11:02AM	BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc (GuruFocus.com)
Aug-24-23 11:30AM	Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak (Zacks)
Aug-23-23 04:10PM	Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22% (Investor's Business Daily) +14.89%
02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals)
09:24AM	How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% (Investor's Business Daily)
Aug-08-23 07:00AM	iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-21-23 08:00PM	ITOS: Lowering target price to $11.00 (Argus Research)
May-13-23 08:03AM	Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher (Simply Wall St.)
May-11-23 06:11AM	iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:01AM	Loading…
07:01AM	iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
May-05-23 08:51AM	iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago (Simply Wall St.)
Apr-26-23 08:00PM	ITOS: What does Argus have to say about ITOS? (Argus Research)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Mar-21-23 06:07AM	Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper (Simply Wall St.)
Mar-17-23 06:18AM	Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook (Simply Wall St.)
Mar-15-23 08:35AM	ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:00AM	iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-28-23 07:00AM	iTeos to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
07:00AM	iTeos to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-09-23 07:00AM	iTeos Provides Business Updates and Clinical Development Plans for 2023 (GlobeNewswire)
Jan-03-23 07:00AM	iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-07-22 08:07AM	Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects? (Simply Wall St.)
Nov-22-22 07:00AM	iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -5.98%
Nov-10-22 07:55PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks) +11.14%
04:01PM	iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-22 05:46PM	Top Biotech Stocks for Q4 2022 (Investopedia)
Nov-02-22 10:00AM	ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-22 08:36AM	Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago (Simply Wall St.)
Aug-12-22 06:16AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.) +7.00%
Aug-10-22 05:25PM	ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:01PM	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jun-30-22 08:41AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
May-16-22 06:27AM	Forecast: Analysts Think iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) Business Prospects Have Improved Drastically (Simply Wall St.)
May-12-22 05:45PM	ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	iTeos Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-11-22 04:09PM	Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer (Investor's Business Daily) -29.77%
07:03AM	Recent 8.9% pullback isn't enough to hurt long-term iTeos Therapeutics (NASDAQ:ITOS) shareholders, they're still up 13% over 1 year (Simply Wall St.)
Apr-08-22 01:00PM	iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022 (GlobeNewswire)
Mar-26-22 02:51PM	Analysts Just Slashed Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) EPS Numbers (Simply Wall St.)
Mar-23-22 05:55PM	ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-22 07:00AM	iTeos to Present at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-24-22 07:55AM	5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates (Zacks) +5.79%
Feb-10-22 07:00AM	iTeos to Participate in Upcoming Investor Conferences in February (GlobeNewswire)
Feb-01-22 09:38AM	Jackson Creek Investment Advisors LLC Buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART ... (GuruFocus.com)
Jan-19-22 09:38AM	Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... (GuruFocus.com)
Jan-10-22 07:00AM	iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Jan-03-22 04:46PM	Why iTeos Therapeutics Topped the Market Today (Motley Fool)
04:01PM	iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-21 05:44PM	iTeos Therapeutics Set to Join S&P SmallCap 600 (PR Newswire)
Dec-29-21 12:19PM	ITeos Therapeutics Inc Insiders are Selling. Investors Should Take Notice (GuruFocus.com)
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... (GuruFocus.com)
09:15AM	Iteos Therapeutics Inc (ITOS) CEO Michel Detheux Sold $2 million of Shares (GuruFocus.com)
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com) +9.23%
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Dec-09-21 04:01PM	iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021 (GlobeNewswire)
Nov-22-21 10:38AM	Notable Iteos Therapeutics Insider Trades $1.1M In Company Stock (Benzinga)
Nov-16-21 12:20PM	Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge (Zacks) +5.79%
11:07AM	Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade (Zacks)
Nov-10-21 05:45PM	ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-04-21 11:24AM	Chief Executive Officer Of Iteos Therapeutics Sold $590K In Stock (Benzinga)
Nov-03-21 07:00AM	iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021 (GlobeNewswire)
Oct-18-21 10:26AM	We're Not Very Worried About iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate (Simply Wall St.)
Sep-02-21 10:11AM	iTeos Therapeutics, Inc. (NASDAQ:ITOS) Is About To Turn The Corner (Simply Wall St.)
Sep-01-21 07:00AM	iTeos Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-21 07:00AM	iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-21 07:00AM	iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021 (GlobeNewswire)
Aug-03-21 07:00AM	iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021 (GlobeNewswire)
Jul-08-21 10:03AM	iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-17-21 06:40AM	The Chief Financial Officer of iTeos Therapeutics, Inc. (NASDAQ:ITOS), Matthew Gall, Just Bought A Few More Shares (Simply Wall St.)
Jun-16-21 02:34PM	Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS (Zacks)
Jun-15-21 08:11AM	Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug (Zacks)
Jun-14-21 04:55PM	Why iTeos Therapeutics Stock Soared Today (Motley Fool) +37.29%
08:42AM	iTeos stock jumps 60% after company announces deal with GSK (MarketWatch)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gall Matthew	Chief Financial Officer	Oct 12 '23	Buy	8.37	5,000	41,850	19,429	Oct 12 05:09 PM
Boxer Capital, LLC		Aug 23 '23	Sale	16.26	350,000	5,692,673	1,804,058	Aug 25 09:28 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ALVR

AlloVir Inc

ITOS

ITeos Therapeutics Inc

Upgrade your FINVIZ experience